Opinion|Videos|September 18, 2024

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

Author(s)Barbara Burtness, MD, Victoria M. Villaflor, MD, Shravan Kandula, MD

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

Episodes in this series

A panel of 3 experts on nasopharyngeal carcinoma

EP. 1 Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

A panel of 3 experts on nasopharyngeal carcinoma

EP. 2 Current Guidelines for Managing Nasopharyngeal Carcinoma

A panel of 3 experts on nasopharyngeal carcinoma

EP. 3 Overview of the JUPITER and POLARIS-2 Trials

A panel of 3 experts on nasopharyngeal carcinoma

EP. 4 Value of PD-L1 Biomarker in NPC

A panel of 3 experts on nasopharyngeal carcinoma

EP. 5 Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

A panel of 3 experts on nasopharyngeal carcinoma

EP. 6 Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

A panel of 3 experts on nasopharyngeal carcinoma

EP. 7 Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

A panel of 3 experts on nasopharyngeal carcinoma

EP. 8 Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

A panel of 3 experts on nasopharyngeal carcinoma

EP. 9 Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

A panel of 3 experts on nasopharyngeal carcinoma

EP. 10 Clinical Scenario: Locally Recurrent NPC

A panel of 3 experts on nasopharyngeal carcinoma

EP. 11 Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

What are the potential benefits of integrating PD-1 inhibitors into standard treatment protocols for NPC?

What does the future look like for PD-1 Inhibitors in NPC?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Pretreated R/M HNSCC: ©Creative Station - stock.adobe.com

August 25th, 2026

Amivantamab Monotherapy Yields Durable Responses in Pretreated R/M HNSCC

Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

August 23rd, 2026

Five Under 5: Top Oncology Videos for the Week of 8/16

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

August 15th, 2026

The OncFive: Top Oncology Articles for the Week of 8/9

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Trending on OncLive

FDA Approves Rusfertide for Polycythemia Vera

The OncFive: Top Oncology Articles for the Week of 8/23

DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer

First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer

FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma